argenx SE (ARGX.BR)
Chart Events
Performance Outlook
| Previous Close | 332.90 |
| Open | 332.60 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 332.40 - 337.00 |
| 52 Week Range | 250.70 - 405.50 |
| Volume | |
| Avg. Volume | 49,267 |
| Market Cap | 18.599B |
| Beta (5Y Monthly) | 0.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -12.08 |
| Earnings Date | May 04, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 441.17 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ARGX.BR
Related Research
- TipRanks
TipRanks ‘Perfect 10’ List: 2 Top Stocks That Analysts Are Placing Their Bets On
The last two weeks have seen the markets take a rollercoaster ride, that’s for sure. The sudden insolvency and failure of Silicon Valley Bank, and the Federal closures of Signature and Silvergate banks, have triggered worries of an old-fashioned bank run. An announcement by Credit Suisse, that it was having difficulty accessing capital, fed fears that even the major banking names would not be immune to contagion. President Biden and Treasury Secretary Yellen have made it clear that account holde
- GlobeNewswire
argenx Announces Annual General Meeting of Shareholders on May 2, 2023
March 17, 2023 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that an Annual General Meeting of shareholders will be held at 12:00 PM CET on Tuesday, May 2, 2023 at Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands. The shareholders and all other persons with meeting rights are invited to attend the Annual Genera
- GlobeNewswire
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis
VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in the UK for the treatment of adults living with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive 68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale compared with 30% of patients treated with placebo (n=19/64) (p<0.0001) during the first treatment cycle in the Phase 3 ADAPT
